The immune system is comprised of two separate active arms of immunity to provide robust protection against disease. The two separate systems of immunity include the innate and adaptive immune ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations ...

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing surveillance, emphasizing the importance of reporting unexpected adverse events to ...

Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemotherapy Ovarian cancer represents a major target ...

Recent findings published in Scientific Reports highlight a promising target for ovarian cancer drug development, emphasizing the importance of Claudin-4 in tumor progression and resistance. The study ...

Response outcomes compared favorably with historical single-agent pembrolizumab activity in recurrent ovarian cancer (KEYNOTE ...

New research by Wistar Institute scientists shows how targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer. The discovery provides a novel ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could ...

A small team at OVACell is fighting ovarian cancer with hidden viral sequences and advanced immunotherapies. The initiative highlights successful stories from projects funded by the European ...

Tracy Brooks, the chair and associate professor of pharmaceutical sciences, Nelly Michura, a junior biology and global public health double major on a pre-med track, Steven Mckay, a fourth-year ...

Ovarian cancer relapse can happen even after successful treatment. Doctors explain key warning signs, recurrence risks, and 5 ...